Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study

Matteo Filippini, Chiara Bazzani, Ennio Giulio Favalli, Antonio Marchesoni, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Francesca Bobbio Pallavicini, Roberto Caporali, Roberto Gorla

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This study aims to compare the efficacy and safety of anti-TNF agents in elderly (aged ≥65 years) and younger patients (aged 18-65 years) with active RA. The study involved 1,114 RA patients treated with anti-TNF drugs and followed-up for >6 months by LORHEN group, who were divided into two cohorts on the basis of their age (311 aged ≥65 and 803 aged

Original languageEnglish
Pages (from-to)90-96
Number of pages7
JournalClinical Reviews in Allergy and Immunology
Volume38
Issue number2-3
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Observational Studies
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Safety
Pharmaceutical Preparations

Keywords

  • Adverse events
  • Elderly patients
  • Elderly-onset rheumatoid arthritis
  • LORHEN database
  • Younger-onset rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis : An observational study. / Filippini, Matteo; Bazzani, Chiara; Favalli, Ennio Giulio; Marchesoni, Antonio; Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Pallavicini, Francesca Bobbio; Caporali, Roberto; Gorla, Roberto.

In: Clinical Reviews in Allergy and Immunology, Vol. 38, No. 2-3, 04.2010, p. 90-96.

Research output: Contribution to journalArticle

Filippini, Matteo ; Bazzani, Chiara ; Favalli, Ennio Giulio ; Marchesoni, Antonio ; Atzeni, Fabiola ; Sarzi-Puttini, Piercarlo ; Pallavicini, Francesca Bobbio ; Caporali, Roberto ; Gorla, Roberto. / Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis : An observational study. In: Clinical Reviews in Allergy and Immunology. 2010 ; Vol. 38, No. 2-3. pp. 90-96.
@article{50b66410342c4d0a9fa364aa0a832352,
title = "Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study",
abstract = "This study aims to compare the efficacy and safety of anti-TNF agents in elderly (aged ≥65 years) and younger patients (aged 18-65 years) with active RA. The study involved 1,114 RA patients treated with anti-TNF drugs and followed-up for >6 months by LORHEN group, who were divided into two cohorts on the basis of their age (311 aged ≥65 and 803 aged",
keywords = "Adverse events, Elderly patients, Elderly-onset rheumatoid arthritis, LORHEN database, Younger-onset rheumatoid arthritis",
author = "Matteo Filippini and Chiara Bazzani and Favalli, {Ennio Giulio} and Antonio Marchesoni and Fabiola Atzeni and Piercarlo Sarzi-Puttini and Pallavicini, {Francesca Bobbio} and Roberto Caporali and Roberto Gorla",
year = "2010",
month = "4",
doi = "10.1007/s12016-009-8142-1",
language = "English",
volume = "38",
pages = "90--96",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis

T2 - An observational study

AU - Filippini, Matteo

AU - Bazzani, Chiara

AU - Favalli, Ennio Giulio

AU - Marchesoni, Antonio

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

AU - Pallavicini, Francesca Bobbio

AU - Caporali, Roberto

AU - Gorla, Roberto

PY - 2010/4

Y1 - 2010/4

N2 - This study aims to compare the efficacy and safety of anti-TNF agents in elderly (aged ≥65 years) and younger patients (aged 18-65 years) with active RA. The study involved 1,114 RA patients treated with anti-TNF drugs and followed-up for >6 months by LORHEN group, who were divided into two cohorts on the basis of their age (311 aged ≥65 and 803 aged

AB - This study aims to compare the efficacy and safety of anti-TNF agents in elderly (aged ≥65 years) and younger patients (aged 18-65 years) with active RA. The study involved 1,114 RA patients treated with anti-TNF drugs and followed-up for >6 months by LORHEN group, who were divided into two cohorts on the basis of their age (311 aged ≥65 and 803 aged

KW - Adverse events

KW - Elderly patients

KW - Elderly-onset rheumatoid arthritis

KW - LORHEN database

KW - Younger-onset rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=77953326679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953326679&partnerID=8YFLogxK

U2 - 10.1007/s12016-009-8142-1

DO - 10.1007/s12016-009-8142-1

M3 - Article

C2 - 19548124

AN - SCOPUS:77953326679

VL - 38

SP - 90

EP - 96

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 2-3

ER -